Malignant Neoplasm of Stomach Completed Phase 2 Trials for Irinotecan (DB00762)

Also known as: Gastric Cancers / Stomach Cancer / Gastric cancer / Gastric Malignancies / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified / Gastric malignancy

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00201747Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach CancerTreatment
NCT00394433Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric CancerTreatment
NCT00857246Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric CancerTreatment
NCT00183872Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction AdenocarcinomaTreatment
NCT00003137Irinotecan in Treating Patients With Advanced Cancer of the StomachTreatment
NCT00003055Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric CancerTreatment
NCT00004235Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or StomachTreatment
NCT00004103Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach CancerTreatment
NCT00003748Irinotecan in Treating Patients With Esophageal or Stomach CancerTreatment
NCT00012363S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the EsophagusTreatment
NCT00020761Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or StomachTreatment
NCT00033657Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal CancerTreatment
NCT00165464Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric CancerTreatment
NCT00166881Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/LeucovorinTreatment
NCT00215995Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric CarcinomasTreatment
NCT00397904Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and CisplatinTreatment
NCT00447967Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric PatientsTreatment
NCT00675194Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric CancerTreatment
NCT00737438Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ AdenocarcinomaTreatment
NCT01138904FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)Treatment
NCT01379482Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric CancerTreatment
NCT01444521Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric CancerTreatment